Curocell
Curocell’s OVISTM technology enhances immune cells to overcome immune suppression in tumor microenvironments.
Funding reportedLast round: Undisclosed round
What company datasets say Curocell raised
Funding, as reported
Reported in all80Bin the source's currency
Rounds4
Last roundUndisclosed round
Last round dateJan 2022
Investors listed19
Biopharma in the same market
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Curocell in front of investors. Or tell us what we have wrong.